We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Western Blotting Processors Market to Reach USD 329 Million by 2028

By LabMedica International staff writers
Posted on 20 Sep 2018
The western blotting processors market is projected to grow at a CAGR of 5.1% from an estimated USD 200 million in 2018 to just under USD 329 million towards the end of 2028, driven partly by the increasing cases of HIV globally as western blot is a confirmed test that can detect anti-HIV antibodies in blood serum samples.

These are the latest findings of Future Market Insights (Valley Cottage, NY, USA), a market intelligence and consulting firm.

The western blotting processors market is highly competitive with the top companies accounting for a major portion of the global sales. More...
Leading companies are acquiring smaller companies and expanding their production capacities to capture a larger share of the global market. Companies in the western blotting processors market are leveraging the available market opportunities to launch their products in full gear in the global market. Product registration followed by commercialization is accelerating the product launch process and creating healthy competition in the global market for western blotting processors. Additionally, manufacturers of western blotting processors are setting up production facilities in other countries to benefit from access to cheap labor and resource expertise, and realign their distribution and customer-oriented strategies.

However, advanced automated western blotting devices, such as high performance western blotting transfer systems, are more highly priced in comparison to their traditional counterparts, thus restricting their adoption in most developing economies. In regions with high labor costs, cheap traditional western blotting processors are still being used to perform protein tests, resulting in time-consuming and high labor cost-inducing processes. Additionally, the global western blotting processors market has witnessed the launch of a few advanced products in recent years. Further, results obtained from the western blotting process are not completely reliable or consistent and the devices are required to be updated regularly for producing more efficient and reliable results. These factors are expected to pose a challenge to the revenue growth of the global western blotting processors market.

Related Links:
Future Market Insights


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.